RxDoctor Payments Data

Craig Peck

Adult Health · Springfield, ORNPI 1811996176

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 174 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations.

$2,683in general payments, 2019–2025

Across 174 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$515
  • AstraZeneca$365
  • Novartis$212
  • E.r. Squibb & Sons, L.L.C.$199
  • Edwards Lifesciences$198
  • Boehringer Ingelheim$166
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$2,683100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,683 in reported general payments places this provider in the 85th percentile of 96 adult health providers in Oregon.

See all adult health providers in Oregon

Medicare billing

Part B allowed, 2024
$38,249
Medicare patients
307
Services billed
417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban375$508,247
XareltoRivaroxaban50$57,743
Repatha SureclickEvolocumab41$42,667
EntrestoSacubitril/Valsartan16$28,683
Praluent PenAlirocumab13$12,696
Repatha SyringeEvolocumab11$8,356
Flecainide Acetate148$7,351
FarxigaDapagliflozin Propanediol12$7,046
Rosuvastatin Calcium268$4,545
Metoprolol Succinate249$3,944
Potassium Chloride99$3,807
Carvedilol340$3,189
Atorvastatin Calcium264$3,134
Torsemide116$3,078
Diltiazem 24hr Er (Cd)Diltiazem Hcl72$2,538

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$46$508,247375 claims
Johnson & JohnsonXarelto$53$57,74350 claims
NovartisEntresto$212$28,68316 claims
AstraZenecaFarxiga$365$7,04612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 96 adult health providers in Oregon.

Other adult health in Springfield

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →